Tongue hyperpigmentation resulting from peginterferon alpha-2a and ribavirin treatment in a Caucasian patient with chronic hepatitis C.
Fernández
A
A
Vázquez
S
S
Rodríguez-González
L
L
D000328:Adult; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D010859:Pigmentation Disorders / Q000139:chemically induced*; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D014059:Tongue / Q000473:pathology*; D044465:White People
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a